Development of oral immunomodulatory agents in the management of multiple sclerosis

The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable. Reducing relapses in trials translates for individuals with MS into a therapeutic aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicholas, Richard, Giannetti, Paolo, Alsanousi, Ali, Friede, Tim, Muraro, Paolo A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100222/
https://www.ncbi.nlm.nih.gov/pubmed/21625416
http://dx.doi.org/10.2147/DDDT.S10498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100222/
https://www.ncbi.nlm.nih.gov/pubmed/21625416
http://dx.doi.org/10.2147/DDDT.S10498

Ejemplares similares